1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Thailand Pharmaceuticals and Healthcare Report Q4 2016

Thailand Pharmaceuticals and Healthcare Report Q4 2016

  • October 2016
  • -
  • Business Monitor International
  • -
  • 102 pages

Includes 3 FREE quarterly updates

BMI View:

Reforms to Thailand's healthcare system will influence the commercial opportunities for multinational drugmakers. While a merger of all three schemes remains difficult, incremental reforms in that direction will be forthcoming and necessary for Thailand to address inequalities in healthcare outcomes. Pressures to ensure the sustainability of the country's healthcare programmes have also not abated. This accentuates the threat of cost containment for drugmakers, which will be heightened should Thailand pursue the target - set by the Committee on Resource Mobilisation for Sustainable Universal Health Coverage - of keeping total health spending less than 5% of GDP by 2022.


Headline Expenditure Projections

- Pharmaceuticals: THB153bn (USD4.5bn) in 2015 to THB161bn (USD4.6bn) in 2016; +5.3% in local currency terms and +1.9% in US dollar terms.

- Healthcare: THB841bn (USD24bn) in 2015 to THB892bn (USD25bn) in 2016: +6.1% in local currency and +2.6% in US dollar terms. In Q416, Thailand remains in the lower half of the Pharmaceutical Risk/Reward Index table that assesses the attractiveness of 19 countries in the Asia Pacific region, with a score of 49.3 out of 100. While Thailand offers relatively attractive revenue-earning opportunities in a regional-comparison for multinational investors, increasing pharmaceutical expenditure is somewhat overshadowed by the prevalent risks in the country including low levels of patent protection.

Table Of Contents

Thailand Pharmaceuticals and Healthcare Report Q4 2016
BMI Industry View 7
Table: Headline Pharmaceuticals and Healthcare Forecasts (Thailand 2014-2020) 7
SWOT 9
Industry Forecast 11
Pharmaceutical Market Forecast 11
Table: Pharmaceutical Sales, Historical Data And Forecasts (Thailand 2012-2020) 13
Healthcare Market Forecast 14
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Thailand 2012-2020) 17
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Thailand 2012-2020) 18
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Thailand 2012-2020) 18
Prescription Drug Market Forecast 19
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Thailand 2012-2020) 21
Patented Drug Market Forecast 22
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Thailand 2012-2020) 23
Generic Drug Market Forecast 24
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Thailand 2012-2020) 25
OTC Drug Market Forecast 26
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Thailand 2012-2020) 28
Pharmaceutical Trade Forecast 29
Table: Pharmaceutical Trade Data And Forecasts (Thailand 2014-2020) 31
Table: Pharmaceutical Trade Data And Forecasts local currency (Thailand 2014-2020) 32
Industry Risk/Reward Index 33
Asia Pacific Risk/Reward Index - Q4 2016 33
Thailand Risk/Reward Index 40
Rewards 40
Risks 40
Regulatory Review 42
Intellectual Property Issues 45
Pricing Regime 46
Table: Price Build-Up Of Medicines In Thailand 46
Reimbursement Regime 46
Market Overview 48
Healthcare Sector 48
Table: Major Health Insurance Programmes In Thailand 50
Table: Healthcare Resources (Thailand 2010-2015) 51
Table: Healthcare Personnel (Thailand 2010-2015) 52
Table: Healthcare Activity (Thailand 2010-2015) 52
Research and Development 52
Thailand Pharmaceuticals and Healthcare Report Q4 2016$$
Clinical Trials 54
Epidemiology 55
Table: Estimated Number Of New Cases Of Cancer In Thailand 58
Competitive Landscape 59
Research-Based Industry 59
Table: PReMA Members 59
Table: Multinational Market Activity 60
Generic Drugmakers 61
Table: Pharmaceutical Manufacturers Of Modern Drugs, 2007-2012 62
Pharmaceutical Distribution 62
Pharmaceutical Retail Sector 63
Company Profile 66
Berlin Pharmaceutical Industry 66
Biolab 69
GlaxoSmithKline 71
Government Pharmaceutical Organisation 74
Merck and Co 78
Novartis 81
Pfizer 84
Sanofi 88
Demographic Forecast 91
Table: Population Headline Indicators (Thailand 1990-2025) 92
Table: Key Population Ratios (Thailand 1990-2025) 92
Table: Urban/Rural Population and Life Expectancy (Thailand 1990-2025) 93
Table: Population By Age Group (Thailand 1990-2025) 93
Table: Population By Age Group % (Thailand 1990-2025) 94
Glossary 96
Methodology 98
Pharmaceutical Expenditure Forecast Model 98
Healthcare Expenditure Forecast Model 98
Notes On Methodology 99
Risk/Reward Index Methodology 100
Index Overview 101
Table: Pharmaceutical Risk/Reward Index Indicators 101
Indicator Weightings 102

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

  • $ 6995
  • Industry report
  • November 2016
  • by GBI Research

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation Summary Asthma is a chronic condition affecting ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.